A Comparison of Pediatric Drug Policy and Development in China and the United States

Abstract

Objective To find the shortcomings of children’s drug research and development policy in China, and to put forward feasible suggestions for encouraging China’s children’s drug research and development by drawing the experience from the United States. Methods To compare the similarities and differences between the policies guiding the use of children’s medicines issued by China and the United States. Results and Conclusion In recent years, the Chinese government has introduced a number of policies, but there is still a big gap in clinical trial design and drug review system compared with the policies of the United States. China should further improve the laws and regulations related to children’s medication, promote the development of clinical trials, develop pricing programs, and expand international cooperation, so as to formulate more scientific and comprehensive guiding principles for the research and development of children’s medication.

Keywords

children’s medication / policies and regulations / implementation effectiveness

References

[1] National Bureau of Statistics. Seventh National Population Census Bulletin (No. 5)[EB/OL]. (2021-05-11)[2024-02-27]. http://www.stats.gov.cn/tjsj/tjgb/rkpcgb/qgrkpcgb/202106/t20210628_1818824.html.

[2] Ni Jingwen. Analysis of adverse drug reactions in pediatrics[J]. Journal of Clinical Rational Drug Use, 2020, 13 (35): 136-137.

[3] US Congress. Pediatric Research Equity Act Amending Section 505B of the Federal Food, Drug & Cosmetic Act (Public Law108-155)[EB/OL]. (2020-02-01)[2024-02- 27]. https://www.gpo.gov/fdsys/pkg/PLAW-108publ155/html/PLAW-108publ155.htm.

[4] FDA. New pediatric labeling information database[EB/OL]. (2020-04-30)[2024-02-27]. https://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=labelingdatabase.

[5] Han Yijing, Gan Jue. Study on incentives for pediatric drug development regulations in the United States and the lessons for China[J]. Chinese Journal of Pharmaceuticals, 2022, 53 (8): 1201-1208.

[6] Xu Shuhong, Zhang Qi, Zhang Linqi, et al. Exploring the development status of pediatric medication in China and thinking at the policy level[J]. The Chinese Journal of Clinical Pharmacology, 2020, 36 (12): 1760-1767.

[7] Hong Jun, Wang Xiaoling, Zhao Zhigang. Implications of EU pediatric medication policy for pediatric medication management in China[J]. Clinical Medication Journal, 2022, 20 (8): 75-79.

[8] Penkov D, Tomasi P, Eichler I, et al. Pediatric medicine development: An overview and comparison of regulatory processes in the European Union and United States[J]. Therapeutic Innovation & Regulatory Science, 2017, 51 (3): 360-371.

[9] FDA. Frequently asked questions on patents and exclusivity[EB/OL]. (2020-02-05)[2024-02-27]. https://www.fda.gov/drugs/development-approval-process-drugs/frequently-asked-questions-patents-and-exclusivity.

[10] FDA. Qualifying for Pediatric Exclusivity under Section 505A of the Federal Food, Drug, and Cosmetic Act: Frequently Asked Questions on Pediatric Exclusivity (505A)[EB/OL]. (2022-03-01)[2024-02-27]. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm077915.Htm.

[11] NICHD. 2020 Best Pharmaceuticals for Children Act (BPCA) Stakeholders Meeting[EB/OL]. (2021-03-01) [2024-02-27]. https://www.nichd.nih.gov/sites/default/ files/inline-files/BPCA12-15-2020StakeholdMeetSum.pdf.

[12] FDA. Pediatric Drug Development under the Pediatric Research Equity Act and the Best Pharmaceuticals for Children Act: Scientific Considerations[EB/OL]. (2023-05-18)[2024-02-27]. https://www.fda.gov/regulatoryinformation/search-fda-guidance-documents/pediatricdrug-development-under-pediatric-research-equity-actand-best-pharmaceuticals-children-act.

[13] National Medical Products Administration. Opinions on Deepening Drug Review and Approval Reform to Further Encourage Innovation[EB/OL]. (2013-02-12) [2024-02-27]. http://www.gov.cn/xinwen/2017-10/08/content_5230105.Htm.

[14] General Office of the State Council. “13th Five-Year” National Food Safety Plan and “13th Five-Year” National Drug Safety Plan[EB/OL]. (2017-02-21)[2024-02- 27]. http://www.gov.cn/zhengce/content/2017-02/21/content_5169755.htm.

[15] National Medical Products Administration. Opinions on Encouraging Drug Innovation to Implement Priority Review and Approval[EB/OL]. (2017-12-28)[2024-02- 27]. http://samr.cfda.gov.cn/WS01/CL0844/220706.html.

[16] Center for Drug Evaluation of National Medical Products Administration. Children’s Drugs (Chemical Drugs) Pharmacy Development Guidelines (for Trial Implementation)[EB/OL]. (2020-12-31)[2024-02- 27]. https://www.cde.org.cn/main/news/viewInfoCommon/95102a5facaf8fd4430d0916a24eab53.

[17] National Medical Products Administration. Pediatric Drugs Clinical Pharmacology Research Technical Guidelines[EB/OL]. (2020-12-31)[2024-02-27]. http://www.cde.org.cn/zdyz.do?method=largePage&id =264.

[18] Center for Drug Evaluation of National Medical Products Administration. Children’s Chemical Drugs Clinical Trials of Improved New Drugs Technical Guiding Principles (for Trial Implementation)[EB/OL]. (2021-09-18)[2024-02-27]. https://www.cde.org.cn/main/fullsearch/fullsearchpage.

[19] Center for Drug Evaluation of National Medical Products Administration. Guiding Principles of Real World Evidence to Support Drug R&D and Review (for Trial Implementation)[EB/OL]. (2020- 01-03)[2024-02-27]. https://www.cde.org.cn/zdyz/downloa-dAtt?idCODE=947400115f0a17db77b141d61f308206.

[20] Hong Jun, Tan Mengmeng, Wang Xiaoling, et al. Comparison of pediatric medication policies between China and Japan[J]. China Pharmaceuticals, 2022, 31 (13): 7-11.

[21] Li Yong, Hu Peijie, Zhang Letong. Comparison of the current situation and incentive policies for pediatric drug development at home and abroad[J]. Chinese Journal of Drug Evaluation, 2023, 40 (1): 12-16.

[22] Li Fengsan, Yu Qin. International development and domestic status of pediatric drug development and pediatric clinical trials[J]. Chinese Journal of New Drugs, 2020, 29 (17): 1933-1938.

[23] Yue Zhihua, Wang Xiaoling, Zhang Wei, et al. Children’s medication regulations in the United States, implementation effectiveness and revelation[J]. Clinical Medication Journal, 2020, 18 (9): 83-87.

Funding

Social Science Project of Shenyang in 2023(SYSK2023-JD-55)